US Biotechnology and Pharmaceuticals: Cognitive neurology KOL discussion: More to keep in mind as the Alzheimer's treatment space evolves

Our recent discussion with Dr. Jack Tsao (NYU) highlighted an Alzheimer's disease market with considerable long-term potential, but a more gradual near-term trajectory as diagnosis, patient segmentation, and specialist capacity evolve. ARIA appears increasingly manageable in experienced hands, while subcutaneous administration and pTau-217 testing could reduce treatment burden and improve referrals. However, cognitive-neurology waitlists remain the primary bottleneck, delaying confirmatory workups and treatment despite patient interest. Important biological questions also persist around dementia subtype, treatment responsiveness, maintenance after plaque clearance, and sequencing of amyloid- and tau-directed therapies. Future entrants will need to match the approximately 30% clinical benefit established by approved anti-amyloids (Lilly's Kisunla and Biogen/Eisai's Leqembi), while efficacy approaching 50% slowing of cognitive decline may be necessary to materially reshape prescribing. N